News | 2020

COVID-19 pandemic

A prospective validation of a urine test for the early and precise prognosis of critical complications in patients with SARS-CoV-2 infection ("Crit-CoV-U") started on July 1st, 2020. This study is financed by the Federal Ministry of Health (BMG), accompanied by the Federal Institute for Drugs and Medical Devices (BfArM) and carried out together with the STAKOB centers of the Robert Koch Institute.

Further information can be found here.


Randomized Controlled Trial published!

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

The PRIORITY study is the first prospective study of CKD273. CKD273 can offer earlier detection of diabetic nephropathy because it can capture changes in multiple disease processes at once.

Using CKD273, we divided 1775 people with type 2 diabetes and normoalbuminuria into a group (of 216 people) who were at high risk for diabetic nephropathy and a low-risk group. During an average follow-up of 2.57 years, 28.2% of people in the high-risk group developed microalbuminuria, defined as a urinary albumin-to-creatinine ratio (UACR) greater than 30 mg/g in at least two of three morning voids, and at least a 30% rise from baseline, or of greater than 40 mg/g. By contrast, just 8.9% of those categorized as low risk developed microalbuminuria. When incorporated into a base model of age, sex, glycated hemoglobin, systolic blood pressure, retinopathy status, estimated glomerular filtration rate (eGFR), and UACR, CKD273 significantly increased the area under the receiver operating characteristic curve.

Further information can be found here.